Patent classifications
C12N9/1241
METHODS OF TARGETED SEQUENCING
Provided herein are methods and compositions for creating a sequencing library comprising a target nucleic acid. Methods herein can comprise: contacting a nucleic acid sample to a first population of primers, a polymerase, dNTPs, and labeled ddNTPs; performing an extension reaction thereby creating an labeled extension product; contacting the extension product to a second population of primers to create a double stranded extension product comprising the target nucleic acid; contacting the double stranded extension product to a target specific enzyme under conditions allowing cleavage of at least a subset of the double stranded extension product thereby creating a cleaved target nucleic acid; and isolating the cleaved target nucleic acid.
FUSION PROTEIN THAT IMPROVES GENE EDITING EFFICIENCY AND APPLICATION THEREOF
Provided are a fusion protein that improves gene editing efficiency and an application thereof. The fusion protein comprises a single-stranded DNA binding protein functional domain, nucleoside deaminase and nuclease. According to CBEs, when carrying our base conversion from C-G to T-A, nucleoside deaminase such as cytosine deaminase carries out deamination by using single-stranded DNA as a substrate, and by re-fusing the single-stranded DNA binding protein functional domain on the fusion protein of the nucleoside deaminase and nuclease, the chance of single-stranded DNA being exposed to the nucleoside deaminase is greatly increased, thereby significantly improving base editing efficiency. The present disclosure provides a breakthrough improvement of single-base gene editing technology and can greatly promote the application thereof in aspects such as gene editing, gene therapy, cell therapy, animal model making, and crop genetic breeding.
VECTOR SET FOR MEASURING TRANSPOSASE ACTIVITY, KIT, TRANSPOSASE ACTIVITY MEASURING METHOD, AND CELL SEPARATION METHOD
According to one embodiment, a vector set includes a first vector and a second vector. The first vector includes a transposase target sequence, a first promoter sequence ligated to downstream of the transposase target sequence, and a first reporter gene ligated to downstream of the first promoter sequence. The second vector includes a 5′-side transposase recognition sequence, a 3′-side transposase recognition sequence, and a first enhancer sequence arranged therebetween.
Inducible control of gene expression
The technology described herein is directed to inducible and repressible polypeptides and polypeptide systems. In particular, described herein are split sequence-specific nucleases and split recombinases that are linked to drug-inducible or drug-repressible dimerization domains. In some embodiments, the polypeptides comprise sequestering domains and/or have their expression controlled by an inducible promoter. In multiple aspects described herein are polynucleotides, vectors, cells, and pharmaceutical compositions comprising said polypeptides or polypeptide systems. Also described herein are methods of using said polypeptide systems to modulate the expression of a target polypeptide or to treat a subject in need of a cell therapy.
DUAL-CONTROLLED DRUG AND PHOTOACTIVATABLE SYSTEM FOR SPATIOTEMPORAL CONTROL OF CELL THERAPY
Provided are compositions, including products of manufacture and kits, and methods, for remotely-controlled and non-invasive manipulation of intracellular nucleic acid expression, genetic processes, function and activity in live cells such as a T cell, a primary T cell, a B cell, a monocyte, a macrophage, a dendritic cell or a natural killercell in vivo, for example, including activating, adding functions or changing or adding specificities for an immune cell, for monitoring physiologic processes, for the correction of pathological processes and for the control of therapeutic outcomes. Provided are tamoxifen-gated photoactivatable split-Cre recombinase optogenetic systems, called TamPA-Cre, that feature high spatiotemporal control to control or alter cell activities in vivo, for example, to limit the activity of a Chimeric Antigen Receptor (CAR)-expressing cell such as an immune cell and its activity at a tumor site for immunotherapy applications.
Hyperactive piggybac transposases
The present invention provides PiggyBac transposase proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.
COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITING
The disclosure provides novel methods and compositions for gene editing. In particular, the disclosure relates to compositions and methods of making nucleic acid donor templates for highly efficient and precise gene editing.
DYNAMIC MULTIPHASE REACTION IN ONE-POT FOR CRISPR/CAS-DERIVED ULTRA-SENSITIVE MOLECULAR DETECTION
Described herein is an aqueous, miscible, multiphase, one-pot detection system including a first phase comprising a low density solution comprising a nucleic acid detection system; and a second phase in diffusive communication with the first phase, the second phase having a higher density than the first phase, and the second phase including a nucleic acid amplification system. Also included are multiwell plates and/or devices including the system and methods of detecting target nucleic acids.
RECOMBINANT THERAPEUTIC INTERVENTIONS FOR CANCER
Described are methods of suppressing the expression of myeloid-derived suppressor cells (MDSCs), M2 macrophages, and Treg cells in a tumor and inducing the expression of macrophages, dendritic cells (DCs), and T effector cells in a tumor in a subject. A pharmaceutical composition comprising a strain of Mycobacteria including an expression vector of the present invention is administered to a subject.
Polymerases
Modified polypeptides having polymerase activity.